These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 33538789

  • 1. Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis.
    Brown GC, Brown MM, Chaudhry I, Stein JD.
    JAMA Ophthalmol; 2021 Apr 01; 139(4):389-397. PubMed ID: 33538789
    [Abstract] [Full Text] [Related]

  • 2. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct 01; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 3. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Monigle MC.
    Ophthalmol Retina; 2024 May 01; 8(5):431-446. PubMed ID: 37981235
    [Abstract] [Full Text] [Related]

  • 4. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC, Brown MM, Turpcu A, Rajput Y.
    Ophthalmology; 2015 Jul 01; 122(7):1416-25. PubMed ID: 25935787
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS, Lane SS.
    Ophthalmology; 2011 Sep 01; 118(9):1834-43. PubMed ID: 21723614
    [Abstract] [Full Text] [Related]

  • 6. Cataract surgery cost utility revisited in 2012: a new economic paradigm.
    Brown GC, Brown MM, Menezes A, Busbee BG, Lieske HB, Lieske PA.
    Ophthalmology; 2013 Dec 01; 120(12):2367-2376. PubMed ID: 24246824
    [Abstract] [Full Text] [Related]

  • 7. A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration.
    Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS.
    Int J Retina Vitreous; 2015 Dec 01; 1():19. PubMed ID: 27847612
    [Abstract] [Full Text] [Related]

  • 8. Cost-utility analysis of cataract surgery in the United States for the year 2018.
    Brown GC, Brown MM, Busbee BG.
    J Cataract Refract Surg; 2019 Jul 01; 45(7):927-938. PubMed ID: 31262482
    [Abstract] [Full Text] [Related]

  • 9. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG, Brown MM, Brown GC, Sharma S.
    Ophthalmology; 2003 Dec 01; 110(12):2310-7. PubMed ID: 14644712
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of cataract surgery. Method to assess cost-effectiveness using registry data.
    Kobelt G, Lundström M, Stenevi U.
    J Cataract Refract Surg; 2002 Oct 01; 28(10):1742-9. PubMed ID: 12388022
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Ophthalmology; 2014 Apr 01; 121(4):936-45. PubMed ID: 24405740
    [Abstract] [Full Text] [Related]

  • 12. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun 01; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 13. A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States.
    Brown GC, Brown MM, Rapuano SB, Boyer D.
    Am J Ophthalmol; 2021 Mar 01; 223():405-429. PubMed ID: 32681907
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
    Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR, Diabetic Retinopathy Clinical Research Network.
    JAMA Ophthalmol; 2016 Aug 01; 134(8):888-96. PubMed ID: 27280850
    [Abstract] [Full Text] [Related]

  • 15. The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited.
    Brown GC, Brown MM, Lieske HB, Turpcu A, Rajput Y.
    Int J Retina Vitreous; 2017 Aug 01; 3():5. PubMed ID: 28289548
    [Abstract] [Full Text] [Related]

  • 16. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH, Lass JH, Brown GC, Brown MM.
    Cornea; 2008 Oct 01; 27(9):1001-7. PubMed ID: 18812762
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK.
    McCarthy G, Fenu E, Bennett N, Almond C.
    Adv Ther; 2019 Mar 01; 36(3):632-644. PubMed ID: 30726549
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
    Holekamp N, Duff SB, Rajput Y, Garmo V.
    J Med Econ; 2020 Mar 01; 23(3):287-296. PubMed ID: 31502893
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Trans Am Ophthalmol Soc; 2013 Sep 01; 111():56-69. PubMed ID: 24167325
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC, IVAN Study Investigators.
    BMJ Open; 2014 Jul 29; 4(7):e005094. PubMed ID: 25079928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.